（文章来源：证券日报） 证券日报网讯 1月15日，圣诺生物发布公告称，经财务部门初步测算，公司预计2025年度实现归属于母 公司所有者的扣除非经常性损益的净利润14，872.70万元至18，590.88万元，与上年同期相比，将增加 10，311.46万元至14，029.64万元，同比增加226.07%至307.58%。 ...

Core Viewpoint - Shengnuo Biotech (688117) forecasts a significant increase in net profit for 2025, projecting a range of 152 million to 190 million yuan, representing a year-on-year growth of 204.42% to 280.53% [1] Group 1 - The company attributes the expected profit growth to the successful implementation of its annual business strategy, focusing on the realization of its production capacity while expanding both domestic and international markets [1] - The demand for the company's peptide raw material business has been steadily increasing, contributing to the overall performance improvement [1] - The anticipated growth further enhances the company's global competitiveness in the peptide pharmaceutical market [1]

Core Viewpoint - Shengnuo Biotech (688117.SH) expects to achieve a net profit attributable to shareholders of the parent company between 152 million to 190 million yuan in 2025, representing a year-on-year increase of 204.42% to 280.53% [1] Group 1 - The company is focusing on its annual business strategy while advancing the construction of its production capacity [1] - There is a continuous expansion of both domestic and international markets, leading to sustained growth in demand for the company's peptide raw material business [1] - The overall performance of the company has significantly improved compared to the same period last year, enhancing its global competitiveness in the peptide pharmaceutical market [1]

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of 152 million to 190 million yuan in 2025, representing a year-on-year increase of 204.42% to 280.53% [1] Group 1: Financial Performance - The projected net profit for 2025 indicates significant growth compared to the previous year, highlighting the company's strong financial trajectory [1] - The anticipated profit growth is driven by increased demand for the company's peptide raw material business, which has seen a steady rise in orders [1] Group 2: Strategic Initiatives - The company is focused on executing its annual business strategy while simultaneously expanding its domestic and international markets [1] - Ongoing capacity expansion efforts are expected to contribute to the overall performance improvement [1] Group 3: Market Position - The company's performance enhancement is expected to strengthen its global competitiveness in the peptide pharmaceutical market [1]

北京商报讯(记者王寅浩宋雨盈)1月15日，圣诺生物发布2025年度业绩预告，预计2025年度实现归属于 母公司所有者的净利润1.52亿—1.9亿元，同比增加204.42%—280.53%；实现归属于母公司所有者的扣 除非经常性损益的净利润1.49亿—1.86亿元，同比增加226.07%—307.58%。 ...

Core Viewpoint - Chengdu Shengnuo Biotechnology Co., Ltd. expects a significant increase in net profit for the fiscal year 2025, projecting a profit of approximately 152 million to 190 million yuan, representing a year-on-year growth of 204.42% to 280.53% [1] Group 1: Financial Performance - The company anticipates a net profit attributable to the parent company of around 152 million to 190 million yuan for 2025 [1] - This projected profit reflects a substantial increase compared to the previous year, indicating strong financial growth [1] Group 2: Business Strategy - The increase in profit is primarily attributed to the company's focus on its annual operational strategy, which includes the successful implementation of ongoing capacity expansion [1] - The company has been actively exploring both domestic and international markets, leading to a sustained growth in demand for its peptide raw material business [1] Group 3: Market Position - The overall performance improvement enhances the company's global competitiveness in the peptide pharmaceutical market [1]

格隆汇1月15日｜圣诺生物公告，经财务部门初步测算，成都圣诺生物科技股份有限公司预计2025年度 实现归属于母公司所有者的净利润15,228.31万元至19,035.38万元，与上年同期相比，将增加10,225.93万 元至14,033.01万元，同比增加204.42%至280.53%。公司预计2025年度实现归属于母公司所有者的扣除 非经常性损益的净利润14,872.70万元至18,590.88万元，与上年同期相比，将增加10,311.46万元至 14,029.64万元，同比增加226.07%至307.58%。 ...

圣诺生物1月15日公告，预计2025年归母净利润1.52亿元-1.9亿元，同比增长204.42%-280.53%。公司预 计2025年度实现归属于母公司所有者的扣除非经常性损益的净利润1.49亿元至1.86亿元，同比增加 226.07%至307.58%。 ...

Core Viewpoint - Shengnuo Bio (688117) expects to achieve a net profit attributable to shareholders of the parent company between 152 million and 190 million yuan for the fiscal year 2025, representing a year-on-year increase of 204.42% to 280.53% [1] Group 1 - The company is focusing on its annual business strategy while advancing the construction of its production capacity [1] - There is a continuous expansion of both domestic and international markets, leading to sustained growth in demand for the company's peptide raw material business [1]

证券代码：688117 证券简称：圣诺生物 公告编号：2026-001 成都圣诺生物科技股份有限公司 2025 年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 公司上年同期利润总额为 6,150.86 万元，归属于母公司所有者的净利润为 5,002.37 万元，归属于母公司所有者扣除非经常性损益后的净利润为 4,561.24 万 元，基本每股收益为 0.45 元。 三、本期业绩变化的主要原因 报告期内，公司紧密围绕年度经营战略，推进在建产能落地的同时，持续开 拓国内外市场，使得公司多肽原料药业务订单需求持续增长，带动公司整体业绩 稳步提升，较上年同期业绩实现大幅增长，进一步增强公司在多肽医药市场的全 球化竞争力。 1 四、风险提示 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 （1）经财务部门初步测算，成都圣诺生物科技股份有限公司（以下简称"公 司"）预计 2025 年度实现归属于母公司所有者的净利润 15,228.31 万元 ...